Naila Khalil1, James R Ebert2, Masato Honda3, Miryoung Lee4, Ramzi W Nahhas5, Antti Koskela6, Thomas Hangartner7, Kurunthachalam Kannan8. 1. Department of Population and Public Health Sciences, Boonshoft School of Medicine, Wright State University, 3123 Research Blvd, Suite #200, Dayton, OH 45420, USA. Electronic address: naila.khalil@wright.edu. 2. The Pediatric Lipid Clinic, Dayton's Children Hospital, One Children's Plaza, Dayton, OH 45404, USA. Electronic address: james.ebert@wright.edu. 3. Wadsworth Center, New York State Department of Health, Albany, NY 12201-0509, USA. Electronic address: Masato.Honda@health.ny.gov. 4. Department of Epidemiology, Human Genetics & Environmental Sciences, The Universit y of Texas Health Science Center School of Public Health, One West University Blvd, SPH Building N1.102B, Brownsville, TX 78520, USA. Electronic address: miryoung.lee@uth.tmc.edu. 5. Department of Population and Public Health Sciences, and Department of Psychiatry, Boonshoft School of Medicine, Wright State University, 3123, Research Blvd, Suite #200, Dayton, OH 45420, USA. Electronic address: ramzi.nahhas@wright.edu. 6. Cancer Research and Translational Medicine Research Unit and MRC Oulu, Faculty of Medicine, University of Oulu, P.O.Box 5000, FIN-90014 Oulu, Finland. Electronic address: antti.koskela@oulu.fi. 7. Wright State University, Dayton, OH, 45435, USA. Electronic address: thomas.hangartner@wright.edu. 8. Wadsworth Center, New York State Department of Health and Department of Environmental Health Sciences, State University of New York, Albany, NY 12201-0509, USA. Electronic address: kurunthachalam.kannan@health.ny.gov.
Abstract
BACKGROUND AND OBJECTIVE: Perfluoroalkyl substances (PFASs), including perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA), have been associated with adverse bone, and metabolic changes in adults. However association of PFASs with bone health in children is understudied. Considering their role as endocrine disruptors, we examined relationships of four PFASs with bone health in children. METHODS: In a cross sectional pilot study, 48 obese children aged 8-12 years were enrolled from Dayton's Children Hospital, Ohio. Anthropometric, clinical and biochemical assessments of serum were completed. Serum PFASs were measured by UPLC-ESI-MS/MS. In a subset of 23 children, bone health parameters were measured using calcaneal quantitative ultrasound (QUS). RESULTS: While PFASs exposure was associated with a consistent negative relationship with bone health parameters, among four PFASs tested, only PFNA showed a significant negative relationship with bone parameter (β [95% CI], = - 72.7 [- 126.0, - 19.6], p = .010). PFNA was also associated with raised systolic blood pressure (p = .008), low density lipoprotein cholesterol (LDL-C; p < .001), and total cholesterol (TC; p = .014). In addition, both PFOA and PFOS predicted elevation in LDL-C, and PFOA predicted increased TC, as well. In this analysis, PFASs were not strongly related to thyroid hormones, 25-hydroxy vitamin D, liver enzymes, or glucose homeostasis. CONCLUSION: PFASs exposure in obese children may play a role in adverse skeletal and cardiovascular risk profiles.
BACKGROUND AND OBJECTIVE:Perfluoroalkyl substances (PFASs), including perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA), have been associated with adverse bone, and metabolic changes in adults. However association of PFASs with bone health in children is understudied. Considering their role as endocrine disruptors, we examined relationships of four PFASs with bone health in children. METHODS: In a cross sectional pilot study, 48 obesechildren aged 8-12 years were enrolled from Dayton's Children Hospital, Ohio. Anthropometric, clinical and biochemical assessments of serum were completed. Serum PFASs were measured by UPLC-ESI-MS/MS. In a subset of 23 children, bone health parameters were measured using calcaneal quantitative ultrasound (QUS). RESULTS: While PFASs exposure was associated with a consistent negative relationship with bone health parameters, among four PFASs tested, only PFNA showed a significant negative relationship with bone parameter (β [95% CI], = - 72.7 [- 126.0, - 19.6], p = .010). PFNA was also associated with raised systolic blood pressure (p = .008), low density lipoprotein cholesterol (LDL-C; p < .001), and total cholesterol (TC; p = .014). In addition, both PFOA and PFOS predicted elevation in LDL-C, and PFOA predicted increased TC, as well. In this analysis, PFASs were not strongly related to thyroid hormones, 25-hydroxy vitamin D, liver enzymes, or glucose homeostasis. CONCLUSION:PFASs exposure in obesechildren may play a role in adverse skeletal and cardiovascular risk profiles.
Authors: Che-Jung Chang; Dana Boyd Barr; P Barry Ryan; Parinya Panuwet; Melissa M Smarr; Ken Liu; Kurunthachalam Kannan; Volha Yakimavets; Youran Tan; ViLinh Ly; Carmen J Marsit; Dean P Jones; Elizabeth J Corwin; Anne L Dunlop; Donghai Liang Journal: Environ Int Date: 2021-11-01 Impact factor: 9.621
Authors: Annelise J Blomberg; Yu-Hsuan Shih; Carmen Messerlian; Louise Helskov Jørgensen; Pál Weihe; Philippe Grandjean Journal: Environ Res Date: 2021-05-31 Impact factor: 8.431
Authors: Rachel Cluett; Shravanthi M Seshasayee; Lisa B Rokoff; Sheryl L Rifas-Shiman; Xiaoyun Ye; Antonia M Calafat; Diane R Gold; Brent Coull; Catherine M Gordon; Clifford J Rosen; Emily Oken; Sharon K Sagiv; Abby F Fleisch Journal: Environ Health Perspect Date: 2019-08-21 Impact factor: 9.031